Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « pulmonary »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
pulmonar < pulmonary < pulse  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 25.
[0-20] [0 - 20][0 - 25][20-24][20-40]
Ident.Authors (with country if any)Title
000001 (2020) A. Prasse [Allemagne] ; F. Bonella [Allemagne] ; U. Müller-Ladner [Allemagne] ; T. Witte [Allemagne] ; N. Hunzelmann [Allemagne] ; J. Distler [Allemagne][Treatment of systemic sclerosis-associated interstitial lung disease].
000003 (2020) Charlotte Girard-Guyonvarc'H ; Michele Iudici[Targeted therapies for connective tissue diseases and vasculitis].
000005 (2020) Tadeusz Płusa[Options for controlling new Corona virus infection - 2019-nCoV].
000006 (2020) Anna Jakubczyc ; Claus Neurohr[Interstitial lung disease in rheumatic diseases - new therapeutic approaches].
000070 (2020) Yasmine F. Ibrahim [Égypte] ; Rabab A. Moussa [Égypte] ; Asmaa M A. Bayoumi [Égypte] ; Al-Shaimaa F. Ahmed [Égypte]Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein.
000079 (2020) Caterina Vacchi [Italie] ; Marco Sebastiani [Italie] ; Giulia Cassone [Italie] ; Stefania Cerri [Italie] ; Giovanni Della Casa [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review
000103 (2020) Champa N. Ratnatunga [Australie] ; Viviana P. Lutzky [Australie] ; Andreas Kupz [Australie] ; Denise L. Doolan [Australie] ; David W. Reid [Australie] ; Matthew Field [Australie] ; Scott C. Bell [Australie] ; Rachel M. Thomson [Australie] ; John J. Miles [Australie]The Rise of Non-Tuberculosis Mycobacterial Lung Disease
000105 (2020) Peter J. Hotez ; Maria Elena Bottazzi ; David B. CorryThe Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement
000125 (2020) Gali Epstein Shochet [Israël] ; Elizabetha Brook [Israël] ; Becky Bardenstein-Wald [Israël] ; David Shitrit [Israël]TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling
000137 (2020) Gui Wang ; Xiao-Rong Jin ; De-Xun JiangSuccessful treatment of adult-onset still disease caused by pulmonary infection-associated hemophagocytic lymphohistiocytosis: A case report
000140 (2020) Yusho Ishii [Japon] ; Hiroshi Fujii [Japon] ; Koichiro Sugimura [Japon] ; Tsuyoshi Shirai [Japon] ; Yosuke Hoshi [Japon] ; Yoko Fujita [Japon] ; Yuko Shirota [Japon] ; Tomonori Ishii [Japon] ; Hiroaki Shimokawa [Japon] ; Hideo Harigae [Japon]Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody
000210 (2020) Thomas Koudstaal ; Karin A. Boomars ; Mirjam KoolPulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
000213 (2020) Ludivine Renaud [États-Unis] ; Willian A. Da Silveira [Royaume-Uni] ; Naoko Takamura [États-Unis] ; Gary Hardiman [États-Unis, Royaume-Uni] ; Carol Feghali-Bostwick [États-Unis]Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis
000214 (2020) Alyson W. Wong [Canada] ; Christopher J. Ryerson [Canada] ; Sabina A. Guler [Suisse]Progression of fibrosing interstitial lung disease
000233 (2020) Giulia Cassone [Italie] ; Marco Sebastiani [Italie] ; Caterina Vacchi [Italie] ; Stefania Cerri [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
000242 (2020) Colin H. Holtze [États-Unis] ; Elizabeth A. Freiheit [États-Unis] ; Susan L. Limb [États-Unis] ; John L. Stauffer [États-Unis] ; Karina Raimundo [États-Unis] ; Wayne T. Pan [États-Unis] ; Kevin R. Flaherty [États-Unis] ; Hyun J. Kim [États-Unis]Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
000243 (2020) Yong-Jian Geng [États-Unis] ; Zhi-Yao Wei [République populaire de Chine] ; Hai-Yan Qian [République populaire de Chine] ; Ji Huang [République populaire de Chine] ; Robert Lodato [États-Unis] ; Richard J. Castriotta [États-Unis]Pathophysiological Characteristics and Therapeutic Approaches for Pulmonary Injury and Cardiovascular Complications of Coronavirus Disease 2019
000245 (2020) Ana Luisa Oliveira [Portugal] ; Carina Ruano [Portugal] ; Nuno Riso [Portugal] ; José Cepeda Ribeiro [Portugal] ; Maria Francisca Moraes-Fontes [Portugal]Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia.
000327 (2020) Jakob Einhaus [Allemagne] ; Ann-Christin Pecher [Allemagne] ; Elisa Asteriti [Allemagne] ; Hannes Schmid [Allemagne] ; Kathy-Ann Secker [Allemagne] ; Silke Duerr-Stoerzer [Allemagne] ; Hildegard Keppeler [Allemagne] ; Reinhild Klein [Allemagne] ; Corina Schneidawind [Allemagne] ; Joerg Henes [Allemagne] ; Dominik Schneidawind [Allemagne]Inhibition of effector B cells by ibrutinib in systemic sclerosis
000387 (2020) Jeffrey P. Jacobs [États-Unis] ; Alfred H. Stammers [États-Unis] ; James St Louis [États-Unis] ; J W Awori Hayanga [États-Unis] ; Michael S. Firstenberg [États-Unis] ; Linda B. Mongero [États-Unis] ; Eric A. Tesdahl [États-Unis] ; Keshava Rajagopal [États-Unis] ; Faisal H. Cheema [États-Unis] ; Tom Coley [États-Unis] ; Vinay Badhwar [États-Unis] ; Anthony K. Sestokas [États-Unis] ; Marvin J. Slepian [États-Unis]Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.
000393 (2020) Dinesh Khanna ; Donald P. Tashkin ; Christopher P. Denton ; Elisabetta A. Renzoni ; Sujal R. Desai ; John VargaEtiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "pulmonary" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "pulmonary" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    pulmonary
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021